CAPTRUST Financial Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$568K	Buy	+15,179	New	+$564K	﹤0.01%	2088
2022 Q3	–	Sell	-1,192	Closed	-$22K	–	2478
2022 Q2	$22K	Hold	1,192	–	–	﹤0.01%	3310
2022 Q1	$26K	Hold	1,192	–	–	﹤0.01%	3227
2021 Q4	$34K	Buy	1,192 +1,169	+5,083%	+$28.8K	﹤0.01%	2939
2021 Q3	$0	Hold	23	–	–	﹤0.01%	4660
2021 Q2	$0	Hold	23	–	–	﹤0.01%	4537
2021 Q1	$0	Buy	+23	New	+$356	﹤0.01%	4390

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAPTRUST Financial Advisors's CRNX Position: Q2 2026 in Review

CAPTRUST Financial Advisors opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 15,179 shares worth $568K. The stake represents ﹤0.01% of the portfolio and ranks #2088 among its holdings. This is a return to the name: CAPTRUST Financial Advisors previously reported a position in CRNX as recently as Q2 2022.

CAPTRUST Financial Advisors first reported a position in CRNX in Q1 2021 and has held it in 7 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

CAPTRUST Financial Advisors held 15,179 shares of Crinetics Pharmaceuticals worth $568K as of Q2 2026.
Crinetics Pharmaceuticals was a new CAPTRUST Financial Advisors position in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2088 holding.
CAPTRUST Financial Advisors first reported a position in Crinetics Pharmaceuticals in Q1 2021 and has held it in 7 quarters since.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.